Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors

Circulation Research

Volumn 82, Issue 8, 1998, Pages 852-861

  Palmer, Daniel ^a   Tsoi, Keith ^a   Maurice, Donald H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

cAMP; Cyclic nucleotide phosphodiesterase; Migration; Platelet derived growth factor; Vascular smooth muscle

Indexed keywords

1,9 DIDEOXYFORSKOLIN; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 4 NITROPHENYL PHOSPHATE; 8 BROMO CYCLIC AMP; BENZYLSULFONYL FLUORIDE; BOVINE SERUM ALBUMIN; CALMODULIN; CILOSTAMIDE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DITHIOTHREITOL; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; LEUPEPTIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; TRITON X 100; TRYPAN BLUE; VINPOCETINE;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

EID: 0032482125     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.8.852     Document Type: Article

References (64)

1. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated process. Cell. 1996;84:359-369.
2. Stossel TP. On the crawling of animal cells. Nature. 1993;260: 1086-1094.
3. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985;56:139-145.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
5. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation. 1992;86:723-729.
6. Grotendorst GR, Seppä HE, Kleinman HK, Martin GR. Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc Natl Acad Sci U S A. 1981;78:3669-3672.
7. 1, receptors. J Clin Invest. 1995;96:141-149.
8. Koyama N, Koshikawa T, Morisaki N, Saito Y, Yoshida S, Bifunctional effects of transforming growth factor-β on migration of cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun. 1990;169:725-729.
9. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-1 and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signalling pathways that are distinct from proliferation. J Clin Invest. 1994;93:1266-1274.
10. Sato Y, Hamanaka R, Ono J, Kuwano M, Rifkin DB, Takaki R. The stimulatory effect of PDGF on vascular smooth muscle cell migration is mediated by the induction of endogenous basic FGF. Biochem Biophys Res Commun. 1991;174:1260-1266.
11. 1, integrin and disassembly of actin filaments. Circ Res. 1997;80:627-637.
12. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994;28:1815-1820.
13. Koyama N, Koshikawa T, Morisaki N, Saito Y, Yoshida S. Secretion of a potent new migration factor for smooth muscle cells (SMC) by cultured SMC. Atherosclerosis. 1991;86:219-226.
14. Autio I, Jaakola O, Solakivi T, Nikkari T. Oxidized low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture. FEBS Lett. 1990;277:247-249.
15. Koyama N, Morisaki N, Saito Y, Yoshida S. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol Chem. 1992;267:22806-22812.
16. Bornfeldt KE, Graves LM, Raines EW, Igarashi Y, Wayman G, Yamamura S, Yatomi Y, Sidhu JS, Krebs EG, Hakomori S, Ross R. Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. J Cell Biol. 1995;130:193-206.
17. Horio T, Kohno M, Kano H, Ikeda M, Yasunari K, Yokokawa K, Minami M, Takeda T. Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res. 1995;77:660-664.
18. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci. 1990;11:150-155.
19. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isozymes. Physiol Rev. 1995;75:725-748.
20. Saeki T, Saito I. Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. Biochem Pharmacol. 1993;46:833-839.
21. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1996;36:403-427.
22. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine, and rat aorta. Biochem Pharmacol. 1986;35:1743-1751.
23. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB. Multiple molecular forms of cyclic nucleotide phosphodiesterases in cardiac and smooth muscle and in platelets: isolation, characterization, and effects of various reference phosphodiesterase and cardiotonic agents. Biochem Pharmacol. 1986;35:787-800.
24. Schoeffter P, Lugnier C, Demesy-Waeldele F, Stoclet JC. Role of cAMPand cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. Biochem Pharmacol. 1987;36:3965-3972.
25. Maurice DH, Crankshaw D, Haslam RJ. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur J Pharmacol. 1991;192:235-242.
26. Hagiwara M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol. 1984; 33:453-457.
27. Ahn HS, Crim W, Pitts B, Sybertz EJ. Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases: tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv Second Messenger Phosphoprotein Res. 1992;25:271-288.
28. Souness JE, Brazdil R, Diocee BK, Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and l-methyl-3-isobutyl-8(methylamino)xanthine. Br J Pharmacol. 1989;98:725-734.
29. Lugnier C, Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilation. Eur Heart J. 1993; 14(suppl I):141-148.
30. Silver PJ. Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesterase. Am J Cardiol. 1989; 62:2A-8A.
31. Kauffman RF, Schenck KW, Utterback BG, Crowe VG, Cohen ML. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther. 1987;242:864-872.
32. Lindgren SHS, Andersson TLG, Vinge E, Andersson K-E. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels. Acta Physiol Scand. 1990;140:209-219.
33. Takahashi S, Oida K, Fujiwara R, Maeda H, Hayashi S, Takai H, Tamai T, Nakai T, Miyabo S. Effect of ciolstazol, a cAMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992;20:900-906.
34. Souness JE, Hassall GA, Parrott DP. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cAMP phosphodiesterase inhibitors. Biochem Pharmacol. 1992;44:857-866.
35. Shirotani M, Yiu Y, Hattori R, Kawai C. U-61,431F, a stable prostacyclin analogue inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins. 1991;41:97-110.
36. Rose RJ, Liu H, Palmer D, Maurice DH. cAMP-mediated regulation of vascular smooth muscle cell cAMP phosphodiesterase activity. Br J Pharmacol. 1997;122:233-240.
37. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 1994;48: 827-835.
38. Hidaka H, Endo T. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase: basic and potential clinical applications. Adv Cyclic Nucleotide Res. 1984;16:245-259.
39. Sheppard H, Wiggan G, Tsien WH. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv Cyclic Nucleotide Res. 1972;1:103-112.
40. Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW, Newman EV. Effects of xanthine derivatives on lipolysis and on adenosine 3′,5′-monophosphate phosphodiesterase activity. Mol Pharmacol. 1970;6:597-603.
41. Pang SC, Venance SL. Cultured smooth muscle approach in the study of hypertension. Can J Physiol Pharmacol. 1992;70:573-579.
42. Davis CW, Daly JW. A simple direct assay of 3′,5′-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-boronate affinity gel chromatography. J Cyclic Nucleotide Res. 1979;5:65-74.
43. Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med. 1962;115:453-466.
44. Connolly DT, Knight MB, Harakas NK, Wittwer AJ, Feder J. Determination of the number of endothelial cells in culture using an acid phosphatase assay. Anal Biochem. 1986;152:136-140.
45. Ross GM, Shamovsky IL, Lawrance G, Sole M, Dostaler SM, Jimmo SL, Weaver DF, Riopelle RJ. Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins. Nat Med. 1997;3:872-878.
46. 3H]hypoxanthine: use in studies of cardiovascular drugs. Anal Biochem. 1993;215:110-117.
47. Poduzuweit T, Nennstiel P, Müller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2hydroxy-3-nonyl) adenine. Cell Signal. 1995;7:733-738.
48. Tanaka K, Honda M, Kuramochi T, Morioka S. Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis. 1994;107: 179-185.
49. Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem. 1993;268:12925-12932.
50. 2-/calmodulin-stimulated cyclic AMP phosphodiesterase (PDEI) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Biochem J. 1995;310:975-982.
51. Wang P, Meyers JG, Wu P, Cheewatrakoolpong B, Egan RW, Billah MM. Expression, purification, and characterization of human cAMPspecific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun. 1997;234:320-324.
52. Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biol Sci. 1997;22:217-224.
53. 2+-linked increase in coupled cAMP synthesis and hydrolysis is an early event in cholinergic and β-adrenergic stimulation of parotid secretion. Proc Natl Acad Sci U S A. 1988;85:7867-7871.
54. Mooradian DL, Fernandes B, Diglio CA, Lester BR. Angiopeptin (BIM23014C) inhibits vascular smooth muscle cell migration in vitro through a G-protein-mediated pathway and is associated with inhibition of adenylyl cyclase and cAMP accumulation. J Cardiovasc Pharmacol. 1995;25:611-618.
55. Rens-Domiano S, Hamm HE. Structural and functional relationships of heterotrimeric G-proteins. FASEB J. 1995;9:1059-1066.
56. Lampugnani MG, Giorgi M, Gaboli M, Dejana E, Marchisio PC. Endothelial cell motility, integrin receptor clustering, and microfilament organization are inhibited by agents that increase intracellular cAMP. Lab Invest. 1990;63:521-531.
57. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation. 1991;84:1273-1278.
58. M cyclic AMP phosphodiesterase in rat aortic smooth muscle [abstract]. FASEB J. 1995;9:A678.
59. 2+ by cAMP in vascular smooth muscle cells. Am J Physiol. 1990;258:C399-C407.
60. Jiang H, Colbran JL, Francis SH, Corbin JD. Direcl evidence for crossactivation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem. 1992;267:1015-1019.
61. 45Ca fluxes in isolated smooth muscle cells. Am J Physiol. 1984;246:C431-C438.
62. Meinkoth JL, Montminy MR, Fink JS, Feramisco JR. Induction of a cAMP-responsive gene in living cells requires the nuclear factor CREB. Mol Cell Biol. 1991;11:1759-1764.
63. Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG. Protein kinase A antagonizes platelet-derived growth factorinduced signalling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1993;90:10300-10304.
64. Graf K, Xi X, Yang D, Fleck E, Hseuh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factordirected migration by vascular smooth muscle cells. Hypertension. 1997; 29:334-339.